Genetics of adult glioma

Cancer Genetics

Volumn 205, Issue 12, 2012, Pages 613-621

  Goodenberger, McKinsey L ^a   Jenkins, Robert B ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Genetics; Glioblastoma; IDH1 and IDH2 mutation; Oligodendroglioma; Single nucleotide polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MICRORNA; MICRORNA 10B; MICRORNA 128; MICRORNA 146B; MICRORNA 15A; MICRORNA 19A; MICRORNA 221; MICRORNA 222; MICRORNA 23; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; UNCLASSIFIED DRUG;

ASTROCYTOMA; CANCER GENETICS; CANCER GRADING; CANCER PROGNOSIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; COPY NUMBER VARIATION; DISEASE PREDISPOSITION; DNA METHYLATION; EGFR GENE; FAMILIAL CANCER; FUBP1 GENE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA; HUMAN; IDH1 GENE; IDH2 GENE; NF1 GENE; OLIGODENDROGLIOMA; ONCOGENE; PATHOPHYSIOLOGY; PDGFRA GENE; PRIORITY JOURNAL; PTEN GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLIOMA; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; MUTATION;

EID: 84872036356     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.10.009     Document Type: Review

References (95)

1. Louis D.N., Ohgaki H., Wiestler O.D., et al. WHO Classification of Tumours of the Central Nervous System 2007, International Agency for Research on Cancer (IARC) Press, Lyon.
2. Wu W., Lamborn K.R., Buckner J.C., et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol 2010, 12:164-172.
3. Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Available at: Accessed on August 16, 2011. http://www.cbtrus.org/2011-npcr-seer/web-0407-report-3-3-2011.pdf.
4. Giannini C., Burger P.C., Berkey B.A., et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 2008, 18:360-369.
5. Bender A.M., Rodriguez F.J., Sarkar G., et al. Tumors of the Nervous System. Cancer Cytogenetics 2009, 597-619. Wiley-Blackwell, Hoboken, New Jersey. 3rd ed. S. Heim, F. Mitelman (Eds.).
6. Bondy M.L., Scheurer M.E., Malmer B., et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008, 113:1953-1968.
7. Karlsson P., Holmberg E., Lundell M., et al. Intracranial tumors after exposure to ionizing radiation during infancy: a pooled analysis of two Swedish cohorts of 28,008 infants with skin hemangioma. Radiat Res 1998, 150:357-364.
8. Inskip P.D., Linet M.S., Heineman E.F. Etiology of brain tumors in adults. Epidemiol Rev 1995, 17:382-414.
9. Ohgaki H., Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005, 109:93-108.
10. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol 2010, 39:675-694.
11. Little M.P., Rajaraman P., Curtis R.E., et al. Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States. BMJ 2012, 344:e1147.
12. Wrensch M., Minn Y., Chew T., et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002, 4:278-299.
13. Schlehofer B., Blettner M., Preston-Martin S., et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer 1999, 82:155-160.
14. Linos E., Raine T., Alonso A., et al. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 2007, 99:1544-1550.
15. Wiemels J.L., Wiencke J.K., Kelsey K.T., et al. Allergy-related polymorphisms influence glioma status and serum IgE levels. Cancer Epidemiol Biomarkers Prev 2007, 16:1229-1235.
16. Wrensch M., Wiencke J.K., Wiemels J., et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 2006, 66:4531-4541.
17. Atlas T.C.G. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
18. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
19. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
20. Verhaak R.G., Hoadley K.A., Purdom E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
21. Huse J.T., Phillips H.S., Brennan C.W. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011, 59:1190-1199.
22. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
23. Brennan C., Momota H., Hambardzumyan D., et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009, 4:e7752.
24. Noushmehr H., Weisenberger D.J., Diefes K., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
25. Gorovets D., Kannan K., Shen R., et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 2012, 18:2490-2501.
26. Kim T.Y., Zhong S., Fields C.R., et al. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006, 66:7490-7501.
27. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002, 21:5427-5440.
28. Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170:1445-1453.
29. Nakamura M., Watanabe T., Yonekawa Y., et al. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G: C --> A: T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001, 22:1715-1719.
30. Nobusawa S., Watanabe T., Kleihues P., et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009, 15:6002-6007.
31. Lu C., Ward P.S., Kapoor G.S., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
32. Turcan S., Rohle D., Goenka A., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
33. Bredel M., Scholtens D.M., Yadav A.K., et al. NFKBIA deletion in glioblastomas. N Engl J Med 2011, 364:627-637.
34. 6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 2005, 113:581-587.
35. 6-alkylguanine. FASEB J 1992, 6:2302-2310.
36. Paz M.F., Yaya-Tur R., Rojas-Marcos I., et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004, 10:4933-4938.
37. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-1354.
38. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
39. Gilbert M.R., Wang M., Aldape K., et al. RTOG 0525: a randomized phase iii trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (DD) schedule in newly diagnosed glioblastoma (GBM). Neuro Oncol 2011, 13:iii51.
40. Singh D., Chan J.M., Zoppoli P., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
41. Ichimura K., Pearson D.M., Kocialkowski S., et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncology 2009, 11:341-347.
42. Christensen B.C., Smith A.A., Zheng S., et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 2011, 103:143-153.
43. Watanabe T., Nobusawa S., Kleihues P., et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174:1149-1153.
44. Houillier C., Wang X., Kaloshi G., et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010, 75:1560-1566.
45. Reifenberger J., Reifenberger G., Liu L., et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994, 145:1175-1190.
46. Cairncross G., Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 2008, 14:352-357.
47. Jenkins R.B., Blair H., Ballman K.V., et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006, 66:9852-9861.
48. Griffin C.A., Burger P., Morsberger L., et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006, 65:988-994.
49. Bettegowda C., Agrawal N., Jiao Y., et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011, 333:1453-1455.
50. Yip S., Butterfield Y.S., Morozova O., et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012, 226:7-16.
51. Cooper L.A., Gutman D.A., Long Q., et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 2010, 5:e12548.
52. Jiao Y., Killela P.J., Reitman Z.J., et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget 2012, 3:709-722.
53. Dubbink H.J., Taal W., van Marion R., et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009, 73:1792-1795.
54. Lujambio A., Ropero S., Ballestar E., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007, 67:1424-1429.
55. Zhang Y., Dutta A., Abounader R. The role of microRNAs in glioma initiation and progression. Front Biosci 2012, 17:700-712.
56. Calin G.A., Sevignani C., Dumitru C.D., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004, 101:2999-3004.
57. He L., He X., Lim L.P., et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
58. Dews M., Homayouni A., Yu D., et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006, 38:1060-1065.
59. Zhou X., Ren Y., Moore L., et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest 2010, 90:144-155.
60. Papagiannakopoulos T., Shapiro A., Kosik K.S. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008, 68:8164-8172.
61. Ciafre S.A., Galardi S., Mangiola A., et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005, 334:1351-1358.
62. Gillies J.K., Lorimer I.A. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 2007, 6:2005-2009.
63. Lukiw W.J., Cui J.G., Li Y.Y., et al. Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). J Neurooncol 2009, 91:27-32.
64. Huse J.T., Brennan C., Hambardzumyan D., et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009, 23:1327-1337.
65. Kim H., Huang W., Jiang X., et al. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci USA 2010, 107:2183-2188.
66. Gabriely G., Yi M., Narayan R.S., et al. Human glioma growth is controlled by microRNA-10b. Cancer Res 2011, 71:3563-3572.
67. Lin J., Teo S., Lam D.H., et al. MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme. Cell Death Dis 2012, 3:e398.
68. Silber J., Jacobsen A., Ozawa T., et al. miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS One 2012, 7:e33844.
69. Rao S.A., Santosh V., Somasundaram K. Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 2010, 23:1404-1417.
70. Roth P., Wischhusen J., Happold C., et al. A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 2011, 118:449-457.
71. Kim T.M., Huang W., Park R., et al. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 2011, 71:3387-3399.
72. Srinivasan S., Patric I.R.P., Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011, 6:e17438.
73. Lindor N.M., McMaster M.L., Lindor C.J., et al. Concise handbook of familial cancer susceptibility syndromes-second edition. J Natl Cancer Inst Monogr 2008, 2008:1-93.
74. Robertson L.B., Armstrong G.N., Olver B.D., et al. Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation. Fam Cancer 2010, 9:413-421.
75. Malmer B., Gronberg H., Bergenheim A.T., et al. Familial aggregation of astrocytoma in northern Sweden: an epidemiological cohort study. Int J Cancer 1999, 81:366-370.
76. Wrensch M., Lee M., Miike R., et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol 1997, 145:581-593.
77. Malmer B., Henriksson R., Gronberg H. Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. Int J Cancer 2003, 106:260-263.
78. Malmer B., Iselius L., Holmberg E., et al. Genetic epidemiology of glioma. Br J Cancer 2001, 84:429-434.
79. de Andrade M., Barnholtz J.S., Amos C.I., et al. Segregation analysis of cancer in families of glioma patients. Genet Epidemiol 2001, 20:258-270.
80. Paunu N., Lahermo P., Onkamo P., et al. A novel low-penetrance locus for familial glioma at 15q23∼q26.3. Cancer Res 2002, 62:3798-3802.
81. Shete S., Lau C.C., Houlston R.S., et al. Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the GLIOGENE consortium. Cancer Res 2011, 71:7568-7575.
82. Wrensch M., Jenkins R.B., Chang J.S., et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 2009, 41:905-908.
83. Shete S., Hosking F.J., Robertson L.B., et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009, 41:899-904.
84. Schwartzbaum J.A., Xiao Y., Liu Y., et al. Inherited variation in immune genes and pathways and glioblastoma risk. Carcinogenesis 2010, 31:1770-1777.
85. Andersson U., Schwartzbaum J., Wiklund F., et al. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol 2010, 49:767-775.
86. Sanson M., Hosking F.J., Shete S., et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet 2011, 20:2897-2904.
87. Stacey S.N., Sulem P., Jonasdottir A., et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 2011, 43:1098-1103.
88. Egan K.M., Nabors L.B., Olson J.J., et al. Rare TP53 genetic variant associated with glioma risk and outcome. J Med Genet 2012, 49:420-421.
89. Jenkins R.B., Wrensch M.R., Johnson D., et al. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet 2011, 204:13-18.
90. Egan K.M., Thompson R.C., Nabors L.B., et al. Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neurooncol 2011, 104:535-542.
91. Simon M., Hosking F.J., Marie Y., et al. Genetic risk profiles identify different molecular etiologies for glioma. Clin Cancer Res 2010, 16:5252-5259.
92. Jenkins R.B., Xiao Y., Sicotte H., et al. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet 2012, 44:1122-1125.
93. Yang H., Dinney C.P., Ye Y., et al. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 2008, 68:2530-2537.
94. Sun Q., Gu H., Zeng Y., et al. Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression. Cancer Sci 2010, 101:2241-2247.
95. Yang R., Schlehe B., Hemminki K., et al. A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat 2010, 121:693-702.